Organization
Combined Rheumatology Practice, Kogarah
3 abstracts
Abstract
APREMILAST MONOTHERAPY AS THE FIRST SYSTEMIC TREATMENT IN DMARD-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 3-YEAR TREATMENT RESULTS Org: Celgene Corporation, West Tennessee Research Institute, Rheumatology and Immunotherapy Center, Franklin, United States of America, Altoona Center for Clinical Research, Duncansville, United States of America, Combined Rheumatology Practice, Kogarah,
Abstract
AC-CUTE: AN OPEN-LABEL STUDY TO EVALUATE NON-PROGRESSION OF STRUCTURAL JOINT DAMAGE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOCILIZUMAB Org: Spire Sciences, Inc., Boca Raton, United States, Combined Rheumatology Practice, Kogarah, Cabrini Medical Centre, Malvern, Barwon Rheumatology Service, Geelong, Roche Products, Pty. Ltd, Dee Why, Australia,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PALACE 4 PHASE 3, RANDOMIZED, CONTROLLED TRIAL Org: Celgene Corporation, University Hospital Southampton NHS Foundation Trust, Rheumatology and Immunotherapy Center, Franklin, United States of America, University of Sheffield, Altoona Center for Clinical Research, Duncansville, United States of America,